A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome (CARIBS)
Primary Purpose
Irritable Bowel Syndrome
Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Traditional dietary advice and low FODMAP content
Low carbohydrate diet
Optimized Medical treatment
Sponsored by
About this trial
This is an interventional supportive care trial for Irritable Bowel Syndrome focused on measuring FODMAPS, carbohydrates, metabolomics, microbiota
Eligibility Criteria
Inclusion Criteria:
- IBS according to ROME IV criteria, BMI 18-35, ability to communicate in Swedish, Gothenburg region resident
Exclusion Criteria:
- Heart, liver, neurologic or psychiatric disease or illness
- Serious gastrointestinal diseases
- Celiac disease
- Diabetes
- Other conditions or surgery that affects the gastrointestinal function
- Hyperlipidemia
- Food allergy or intolerance other than lactose
- Adherence to a specific diet
- Being pregnant or breastfeeding
- Previously been treated with any of the intervention arms, including having tested all of the pharmacological treatment options of relevance for the symptom profile of the patient
Sites / Locations
- Magnus Simren
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Experimental
Arm Label
Diet A
Medical treatment
Diet B
Arm Description
Low carbohydrate diet
Optimized Medical treatment
Traditional dietary advice and low FODMAP content
Outcomes
Primary Outcome Measures
The proportion (%) of patients who respond to treatment
A responder is defined as having an IBS-SSS reduction >50 points @ 4 weeks
Secondary Outcome Measures
Change in symptom severity
Absolute and percentage change in IBS-SSS
Determinants for GI symptoms by IBS-SSS
GI symptoms measured by IBS-SSS
Determinants for GI symptoms by GSRS-IBS
GI symptoms measured by GSRS-IBS
Predictors of response to treatment
Potential predictors include demographics, questionnaire data, microbiota, metabolites, immunology
Adherence to allocated intervention
Including compliance to dietary intervention during 4 weeks, and long-term adherence during follow-up
Change in microbiota content
Fecal microbiota analysis using 16S technique
Change in extra-intestinal symptoms and quality of life
As assessed by IBS specific questionnaires
Change in metabolic profile
Metabolomics in serum and urine samples
Full Information
NCT ID
NCT02970591
First Posted
November 18, 2016
Last Updated
October 24, 2022
Sponsor
Sahlgrenska University Hospital, Sweden
1. Study Identification
Unique Protocol Identification Number
NCT02970591
Brief Title
A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome
Acronym
CARIBS
Official Title
The Role of CARbohydrates in Irritable Bowel Syndrome (CARIBS): Protocol for a Randomized Controlled Trial Comparing Three Different Treatment Options
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
January 2017 (undefined)
Primary Completion Date
April 15, 2022 (Actual)
Study Completion Date
April 29, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sahlgrenska University Hospital, Sweden
4. Oversight
5. Study Description
Brief Summary
Irritable Bowel Syndrome is a common disease to which there is no curable treatment. Diet is considered to trigger symptoms associated with the clinical picture of IBS, and dietary treatment is thus believed to relieve the symptoms of IBS. As the disease is very heterogeneous in its manifestation, different treatment options might be indicated depending on the predominant symptom. To investigate the response to different dietary treatment options, a randomized controlled intervention trial will be carried out in adult patients (>18 y) with IBS according to Rome IV criteria. The aim of this study is to compare the response to two different dietary treatments or optimized medical treatment.
Detailed Description
The study is a randomized controlled trial comparing three different treatments during four weeks:
Combination of low FODMAP diet + traditional dietary advice (based on NICE recommendations)
Eat at regular hours; 3 main meals and 3 snacks
Eat in peace, chew the food properly
Peel all fruits and vegetables
Limit intake of spicy and fatty foods, coffe, alcohol, avoid fizzy drinks and chewing gum
Choose soluble rather than insoluble fibres
Avoid foods high in FODMAPs
Diet low in carbohydrates
10 E% carbohydrates, 23 E% protein, 67 E% fat
Larger amounts of fish, shellfish, meat, egg, dairy products (lactose free if wanted) nuts, seeds, oil, vegetables
No sugary or starchy foods, e.g pasta, potatoes, bread, rice, most fruits
No specific consideration about FODMAP content
Optimized pharmacological tretament based on predominant symptom and previous experience with pharmacological treatmment.
Pain/discomfort:
Pain: Amitriptyline 25 mg. Increase to 50 mg if needed
Episodic pain: Hyoscyamine 0,2mg 2x2; adjust dose if needed
Pain with diarrhea: Amitriptyline 25 mg. Increase dose if needed
Pain with constipation: Linaclotide 290 microgram 1x1
Constipation:
Bulking agent (Sterculia gum (Inolaxol) 1x1. Increase to 1x3 if needed
Osmotic laxative (Macrogol (Movicol) 1x1
Linaclotide 290 microgram 1x1 Diarrhea
Loperamide 1x2 . Adjust dose if needed
Cholestyramine 1x1. Increase ever 3-5 d as needed
Ondansetron 4mg 1x1. Increase to 1x2-3 if needed
Eluxadoline 100mg 1x2
Primary endpoint: IBS-SSS reduction >50 points
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Irritable Bowel Syndrome
Keywords
FODMAPS, carbohydrates, metabolomics, microbiota
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Diet A
Arm Type
Experimental
Arm Description
Low carbohydrate diet
Arm Title
Medical treatment
Arm Type
Active Comparator
Arm Description
Optimized Medical treatment
Arm Title
Diet B
Arm Type
Experimental
Arm Description
Traditional dietary advice and low FODMAP content
Intervention Type
Other
Intervention Name(s)
Traditional dietary advice and low FODMAP content
Intervention Description
Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.
Intervention Type
Other
Intervention Name(s)
Low carbohydrate diet
Intervention Description
Diet that contains a maximum of 10 energy percent of carbohydrates, 23 energy % proteins and 67 energy % fat.
Intervention Type
Other
Intervention Name(s)
Optimized Medical treatment
Intervention Description
Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.
Primary Outcome Measure Information:
Title
The proportion (%) of patients who respond to treatment
Description
A responder is defined as having an IBS-SSS reduction >50 points @ 4 weeks
Time Frame
Baseline to 4 weeks
Secondary Outcome Measure Information:
Title
Change in symptom severity
Description
Absolute and percentage change in IBS-SSS
Time Frame
Baseline, 4 weeks, 3 and 6 months
Title
Determinants for GI symptoms by IBS-SSS
Description
GI symptoms measured by IBS-SSS
Time Frame
Baseline, 4 weeks, 3 and 6 months
Title
Determinants for GI symptoms by GSRS-IBS
Description
GI symptoms measured by GSRS-IBS
Time Frame
Baseline, 4 weeks, 3 and 6 months
Title
Predictors of response to treatment
Description
Potential predictors include demographics, questionnaire data, microbiota, metabolites, immunology
Time Frame
Baseline to 4 weeks
Title
Adherence to allocated intervention
Description
Including compliance to dietary intervention during 4 weeks, and long-term adherence during follow-up
Time Frame
Baseline, 4 weeks, 3 and 6 months
Title
Change in microbiota content
Description
Fecal microbiota analysis using 16S technique
Time Frame
Baseline, 4 weeks, 6 months
Title
Change in extra-intestinal symptoms and quality of life
Description
As assessed by IBS specific questionnaires
Time Frame
Baseline, 4 weeks, 3 and 6 months
Title
Change in metabolic profile
Description
Metabolomics in serum and urine samples
Time Frame
Baseline, 4 weeks, 6 months
Other Pre-specified Outcome Measures:
Title
Qualitative assessment
Description
Patient's subjective experiences related to the dietary intervention described by qualitative methods.
Time Frame
Approx. at 3 months follow-up
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
IBS according to ROME IV criteria, BMI 18-35, ability to communicate in Swedish, Gothenburg region resident
Exclusion Criteria:
Heart, liver, neurologic or psychiatric disease or illness
Serious gastrointestinal diseases
Celiac disease
Diabetes
Other conditions or surgery that affects the gastrointestinal function
Hyperlipidemia
Food allergy or intolerance other than lactose
Adherence to a specific diet
Being pregnant or breastfeeding
Previously been treated with any of the intervention arms, including having tested all of the pharmacological treatment options of relevance for the symptom profile of the patient
Facility Information:
Facility Name
Magnus Simren
City
Gothenburg
State/Province
Non-US/Non-Canadian
ZIP/Postal Code
44331
Country
Sweden
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
35037893
Citation
Nybacka S, Tornblom H, Simren M, Storsrud S. The Role of Carbohydrates in Irritable Bowel Syndrome: Protocol for a Randomized Controlled Trial Comparing Three Different Treatment Options. JMIR Res Protoc. 2022 Jan 17;11(1):e31413. doi: 10.2196/31413.
Results Reference
derived
PubMed Identifier
34560607
Citation
Algera JP, Storsrud S, Lindstrom A, Simren M, Tornblom H. Gluten and fructan intake and their associations with gastrointestinal symptoms in irritable bowel syndrome: A food diary study. Clin Nutr. 2021 Oct;40(10):5365-5372. doi: 10.1016/j.clnu.2021.09.002. Epub 2021 Sep 9.
Results Reference
derived
Learn more about this trial
A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome
We'll reach out to this number within 24 hrs